PE20181803A1 - Inhibidores de mcl-1 macrociclicos para tratar el cancer - Google Patents
Inhibidores de mcl-1 macrociclicos para tratar el cancerInfo
- Publication number
- PE20181803A1 PE20181803A1 PE2018001558A PE2018001558A PE20181803A1 PE 20181803 A1 PE20181803 A1 PE 20181803A1 PE 2018001558 A PE2018001558 A PE 2018001558A PE 2018001558 A PE2018001558 A PE 2018001558A PE 20181803 A1 PE20181803 A1 PE 20181803A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitors
- treat cancer
- mcl
- compounds
- refers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title abstract 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 210000000066 myeloid cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA (I) QUE ES EL ACIDO 17-CLORO-5,13,14,22-TETRAMETIL-28-OXA-2,9-DITIA-5,6,12,13,22-PENTAAZAHEPTACICLO[27.7.1.1 4,7. 0 11,15. 0 16,21. 0 20,24. 0 30,35]OCTATRIACONTA-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-TRIDECAENO-23-CARBOXILICO, ASI COMO COMPUESTOS DE FORMULAS (II) Y (III). TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA 1 DE LEUCEMIA DE CELULAS MIELOIDES (Mcl-1) SIENDO UTILES PARA REDUCIR O INHIBIR EL CRECIMIENTO DE UN TUMOR O LA PROLIFERACION DE CELULAS CANCEROSAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181803A1 true PE20181803A1 (es) | 2018-11-19 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001558A PE20181803A1 (es) | 2016-04-22 | 2017-04-21 | Inhibidores de mcl-1 macrociclicos para tratar el cancer |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US9840518B2 (es) |
| EP (1) | EP3445767B1 (es) |
| JP (1) | JP6894449B2 (es) |
| KR (1) | KR102388208B1 (es) |
| CN (1) | CN109071566B (es) |
| AR (1) | AR108301A1 (es) |
| AU (1) | AU2017252222B2 (es) |
| BR (1) | BR112018070677B1 (es) |
| CA (1) | CA3020378A1 (es) |
| CL (1) | CL2018002410A1 (es) |
| CO (1) | CO2018008759A2 (es) |
| CR (1) | CR20180499A (es) |
| CY (1) | CY1123186T1 (es) |
| DK (1) | DK3445767T3 (es) |
| DO (1) | DOP2018000222A (es) |
| EA (1) | EA036551B1 (es) |
| ES (1) | ES2791319T3 (es) |
| HR (1) | HRP20200673T1 (es) |
| HU (1) | HUE049591T2 (es) |
| IL (1) | IL262237B (es) |
| LT (1) | LT3445767T (es) |
| MA (1) | MA44721B1 (es) |
| ME (1) | ME03729B (es) |
| MX (1) | MX386103B (es) |
| NI (1) | NI201800093A (es) |
| PE (1) | PE20181803A1 (es) |
| PH (1) | PH12018502227A1 (es) |
| PL (1) | PL3445767T3 (es) |
| PT (1) | PT3445767T (es) |
| RS (1) | RS60257B1 (es) |
| SG (1) | SG11201805838UA (es) |
| SI (1) | SI3445767T1 (es) |
| SM (1) | SMT202000249T1 (es) |
| SV (1) | SV2018005742A (es) |
| TN (1) | TN2018000319A1 (es) |
| TW (1) | TWI742074B (es) |
| WO (1) | WO2017182625A1 (es) |
| ZA (1) | ZA201807766B (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017136731A1 (en) | 2016-02-04 | 2017-08-10 | The Johns Hopkins University | Rapaglutins, novel inhibitors of glut and use thereof |
| AU2017214557B2 (en) | 2016-02-04 | 2022-05-19 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| TWI742074B (zh) | 2016-04-22 | 2021-10-11 | 瑞典商阿斯特捷利康公司 | Mcl-1抑制劑及其使用方法 |
| EP3458459B1 (en) | 2016-05-19 | 2022-04-27 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
| TWI781996B (zh) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| WO2019035911A1 (en) | 2017-08-15 | 2019-02-21 | Abbvie Inc. | MACROCYCLIC INHIBITORS OF MCL-1 AND METHODS OF USE |
| WO2019035914A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE |
| WO2019096909A1 (en) * | 2017-11-17 | 2019-05-23 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
| US11447504B2 (en) | 2017-11-17 | 2022-09-20 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| US11478451B1 (en) | 2017-11-17 | 2022-10-25 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| WO2019096907A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| WO2019096911A1 (en) | 2017-11-17 | 2019-05-23 | The Broad Institute, Inc. | Macrocyclic indole derivatives |
| WO2019096922A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Substituted macrocyclic indole derivatives |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| MX2021003655A (es) * | 2018-09-30 | 2021-06-23 | Jiangsu Hengrui Medicine Co | Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina. |
| TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| CN110845520B (zh) * | 2018-11-22 | 2021-04-13 | 苏州亚盛药业有限公司 | 作为mcl-1抑制剂的大环吲哚 |
| WO2020151738A1 (en) * | 2019-01-23 | 2020-07-30 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
| EP3924358A4 (en) * | 2019-03-08 | 2023-07-05 | Zeno Management, Inc. | Macrocyclic compounds |
| TW202106693A (zh) * | 2019-04-30 | 2021-02-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚類大環衍生物、其製備方法及其在醫藥上的應用 |
| EA202193076A1 (ru) | 2019-05-10 | 2022-02-16 | Янссен Байотек, Инк. | Макроциклические хелаторы и способы их применения |
| EP3969457B1 (en) | 2019-05-17 | 2025-08-13 | The Broad Institute Inc. | Methods of preparing macrocyclic indoles |
| WO2020236825A2 (en) | 2019-05-20 | 2020-11-26 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| US20220306653A1 (en) * | 2019-06-21 | 2022-09-29 | Janssen Pharmaceutica Nv | Macrocyclic inhibitors of mcl-1 |
| MX2022000390A (es) | 2019-07-09 | 2022-02-10 | Janssen Pharmaceutica Nv | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. |
| US20220372014A1 (en) * | 2019-10-01 | 2022-11-24 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CN114728985A (zh) * | 2019-11-21 | 2022-07-08 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环吲哚衍生物 |
| AU2020388974A1 (en) * | 2019-11-21 | 2022-07-07 | Janssen Pharmaceutica Nv | Macrocyclic sulfonyl derivatives as MCL-1 inhibitors |
| CA3162963A1 (en) * | 2019-12-18 | 2021-06-24 | Zeno Management, Inc. | Macrocyclic compounds |
| CA3168355A1 (en) | 2020-02-21 | 2021-08-26 | Frederik Jan Rita Rombouts | Macrocyclic indole derivatives as inhibitors of mcl-1 |
| TW202144368A (zh) * | 2020-03-30 | 2021-12-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 吲哚類大環衍生物的結晶形式及其製備方法 |
| AU2021278292A1 (en) | 2020-05-29 | 2023-02-09 | Janssen Pharmaceutica Nv | Macrocyclic 7-pyrazol-5-YL-indole derivatives as inhibitors of MCL-1 |
| AU2021291056A1 (en) | 2020-06-19 | 2023-02-23 | Janssen Pharmaceutica Nv | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of MCL-1 |
| CN115943146A (zh) | 2020-06-19 | 2023-04-07 | 詹森药业有限公司 | N-连接的大环4-(吡唑-5-基)-吲哚衍生物作为mcl-1抑制剂 |
| CN115776888A (zh) | 2020-07-08 | 2023-03-10 | 詹森药业有限公司 | 含大环醚的吲哚衍生物作为mcl-1抑制剂 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| CA3202759A1 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| ES3018757T3 (en) | 2020-12-17 | 2025-05-19 | Janssen Pharmaceutica Nv | Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| AU2022220818A1 (en) | 2021-02-12 | 2023-09-28 | Janssen Pharmaceutica Nv | Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| CN115490708B (zh) * | 2021-06-18 | 2025-01-24 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| IL317101A (en) | 2022-05-20 | 2025-01-01 | Novartis Ag | Antibody-drug conjugates of anticancer compounds and methods of using them |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009011210A (es) | 2007-04-16 | 2009-10-30 | Abbott Lab | Inhibidores de mcl1 de indol 7-no sustituido. |
| EP2134684B1 (en) * | 2007-04-16 | 2017-08-02 | AbbVie Inc. | 7-substituted indole as mcl-1 inhibitors |
| DK2379580T3 (da) * | 2008-12-22 | 2014-01-20 | Cubist Pharm Inc | Hidtil ukendte antibakterielle midler til behandling af gram-positive infektioner |
| EA201200855A1 (ru) * | 2009-12-23 | 2013-04-30 | Айронвуд Фармасьютикелз, Инк. | Модуляторы crth2 |
| HRP20220319T1 (hr) * | 2011-05-19 | 2022-05-13 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Makrociklički spojevi kao inhibitori protein kinaze |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| EP3038618B1 (en) | 2013-08-28 | 2020-10-14 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| EP3105236B1 (en) * | 2014-02-12 | 2017-10-18 | ViiV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| EP3122353B1 (en) | 2014-03-27 | 2020-10-28 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| SG11201608430RA (en) * | 2014-04-11 | 2016-11-29 | Bayer Pharma AG | Novel macrocyclic compounds |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| TWI742074B (zh) | 2016-04-22 | 2021-10-11 | 瑞典商阿斯特捷利康公司 | Mcl-1抑制劑及其使用方法 |
-
2017
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es active IP Right Grant
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active Active
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en not_active Ceased
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 CA CA3020378A patent/CA3020378A1/en active Pending
- 2017-04-21 MX MX2018012711A patent/MX386103B/es unknown
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 SM SM20200249T patent/SMT202000249T1/it unknown
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181803A1 (es) | Inhibidores de mcl-1 macrociclicos para tratar el cancer | |
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
| MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
| CU20190086A7 (es) | Compuestos de heteroarilo bicíclicos 6-6 fusionados útiles como inhibidores de lats | |
| MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
| CL2018002516A1 (es) | Inhibidores de mcl-1 indólicos sustituidos. | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| CO2018004964A2 (es) | Compuestos útiles como inmunomoduladores | |
| CO2018006164A2 (es) | Compuestos útiles como inhibidores de cinasa | |
| EA201690584A1 (ru) | Пестициды на основе замещенного гетероциклом бициклического азола | |
| CR20110059A (es) | Compuestos organicos | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| CL2015001649A1 (es) | Dispersion solida fisicamente estable del acido 4-{[(2r,3s,4r,5s)-4-(4-cloro-2-fluorofenil)-4-ciano-5-(2,2-dimetilpropil)-pirrolidin-2-carbonil]-amino}-3-metoxibenzoico; formulacion solida; metodo de preparacion; preparacion farmaceutica; uso para tratar el cancer, en particular leucemia mieloide aguda o cancer de prostata. | |
| UY36285A (es) | Compuestos que inhiben la proteína mcl-1 | |
| CU24385B1 (es) | Compuestos éteres de arilo útiles para tratar cancer de célula renal | |
| CL2017001336A1 (es) | Nuevos aminoácidos ester fosforamidatos 2' y/o 5', 3' deoxiadenosina derivativos como compuestos anticancerígenos | |
| CU20150053A7 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| ECSP088536A (es) | DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| PE20180231A1 (es) | Compuestos nucleosidos 5'-sustituidos | |
| CO2018005639A2 (es) | Sililfenoxiheterociclos trisustituidos y análogos | |
| PE20210002A1 (es) | Sales de derivados de pirrolotriazina utiles como inhibidores tam | |
| EA201790779A1 (ru) | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений | |
| CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos |